1-chloro-3-(1,2,3)-triazol-2-ylpropan-2-ol | 452105-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-chloro-3-(1,2,3)-triazol-2-ylpropan-2-ol
• 英文别名: 1-Chloro-3-(triazol-2-yl)propan-2-ol
• CAS: 452105-40-7
• 化学式: C₅H₈ClN₃O
• mdl: MFCD19233176
• 分子量: 161.591
• InChiKey: QQQNZMOOPDFEBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-[1,2,3]triazole 、 环氧氯丙烷 生成 1-chloro-3-(1,2,3)-triazol-2-ylpropan-2-ol
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Treatment of acute myeloid leukemia with indolinone compounds
  申请人：SUGEN, Inc.

  公开号：US20030130280A1

  公开（公告）日：2003-07-10

  A method of treating acute myeloid leukemia in patient positive for FLT-3-ITD is described. The treatment is accomplished by administration of a compound of Formula I or II as defined herein.

  描述了一种治疗FLT-3-ITD阳性患者急性髓系白血病的方法。该治疗通过给予本文中定义的I或II式化合物来实现。
• Treatment of excessive osteolysis with indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20040209937A1

  公开（公告）日：2004-10-21

  Compounds of Formula I and Formula II, as described herein, are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. The compounds also are useful for inhibiting phosphorylation of CSF1R, and for treating cancers that express CSF1R.

  本文描述的式I和式II的化合物可用于治疗过度骨溶解，通过抑制M-CSF介导的破骨细胞发育。这些化合物还可用于抑制CSF1R的磷酸化，并用于治疗表达CSF1R的癌症。
• 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20030092917A1

  公开（公告）日：2003-05-15

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药用可接受的盐，这些化合物可以调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20040102510A1

  公开（公告）日：2004-05-27

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，其调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
  申请人：SUGEN, Inc.

  公开号：US20040152759A1

  公开（公告）日：2004-08-05

  The invention relates to a method of treating cancer by administering a combination of an indolinone compound with another chemotherapeutic agent. The combination of an indolinone compound of Formula I: 1 with another chemotherapeutic agent provides an enhanced effect in treating cancer patients.

  本发明涉及一种治疗癌症的方法，通过给予一种吲哚酮化合物和另一种化疗药物的组合物。一种式子为I：1的吲哚酮化合物与另一种化疗药物的组合物在治疗癌症患者方面提供了增强效果。